Although previous trials involving the use of PD-1/PDL1 checkpoint inhibitors in colorectal cancer patients could not demonstrate a clear benefit [51], we rely on the fact that avelumab 10 mg/kg once every 2 weeks has demonstrated meaningful clinical activity across various treatment settings and tumor types, including MCC and RCC. This evidence concerns the gene CD274 and Merkel cell skin cancer.